Effect of ostarine on glucose level, lipid profile, and osteoporosis in streptozotocin induced diabetic male rats.

This study aimed to evaluate ostarine effects on blood glucose, dyslipidemia, and osteoporosis in diabetic rats. Forty-eight adult male rats were divided into six groups (Control, Ostarine: 0.4 mg/kg daily orally, diabetes mellitus (DM), DO: diabetic rats received ostarine, DI: diabetic rats received insulin, DOI: diabetic rats received ostarine and insulin for 8 weeks). Radiographic examination for bone was done. Blood samples, bone, and pancreas were taken for examination. Ostarine significantly increased body weight, muscle weight, bone weight and ashing, lowered blood glucose, TC, low-density lipoprotein-cholesterol (LDL-C), and triglycerides, increased Ca++, phosphorus (P), osteocalcin, RUNX2, and positive immunostained osteopontin cells compared to DM, but no significance on CTX-I or RANKL. It improved bone density in X-ray, pancreatic islet cells and bone microarchitecture in histological examinations, being more apparent in ostarine and insulin-treated group. However, insulin alone had no significant effect on TC, LDL-C, Ca++, P, OC, CTX-I, RUNX2, RANKL, or osteopontin and downregulated alkaline phosphatase compared to DM, with focal decreased bone radiodensity and minimal improvement in bone and pancreatic sections. In conclusion, ostarine could have beneficial effects on diabetes such as improving glycemic state, dyslipidemia, and mainly diabetic osteoporotic bone. Ostarine should be further evaluated in diabetic osteoporosis or other types of osteoporosis.